Merck, SML1687-5MG, 3BDO

Application
3BDO has been used to investigate the potential effects of metformin on inflammatory lung injury.
Biochem/physiol Actions
3BDO is a cell-permeable, orally bioavailable, non-toxic butyrolactone derivative that is shown to competitively bind FKBP1A (FK506-binding protein 1A, 12 kDa) in a reversible manner, and suppress autophagy via the mTOR pathway. 3BDO inhibits both LPS- and oxLDL-induced autophagy in HUVECs, increases TIA1 phosphorylation, and reduces autophagosomes number. It is reported to be brain permeant, and significantly decreases atherosclerosis development in apoE-/- mice (100 mg/kg, q.d., p.o.). 3BDO increases IDE and neprilysin levels, lowers amyloid-β deposition in an AβPP/PS1 transgenic mouse model of Alzheimer′s disease, and alleviates memory deficits.
An orally bioavailable, brain-permeant suppressor of mTOR-mediated autophagy; reduces Aβ levels and prevents cognitive deficits in AβPP/PS1 mouse model.
An orally bioavailable, brain-permeant suppressor of mTOR-mediated autophagy; reduces Aβ levels and prevents cognitive deficits in AβPP/PS1 mouse model.
3-benzyl-5-[(2-nitrophenoxy) methyl]-dihydrofuran-2 (3H)-one (3BDO) blocks rise in LC3-II stimulated by uric acid (UA). It protects the capability of Rheb1-deficient macrophages to perform phagocytosis. 3BDO also prevents the inhibitory effects of EX-527 on eukaryotic translation initiation factor-binding protein 1(4E-BP1) phosphorylation.